Monorem R (Isosorbide Mononitrate)

Isosorbide mononitrate is converted in the body to nitric oxide, a potent vasodilator. Nitric oxide activates guanylate cyclase, raising cyclic GMP levels in vascular smooth muscle, which relaxes the vessels, lowers cardiac workload, and decreases the heart’s oxygen demand.

The appropriate dose of Monorem R is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the dosing instructions provided by their healthcare professional.

Safety data for isosorbide mononitrate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To request Monorem R, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Monorem R belongs to the nitrate class, offering long‑acting vasodilation, whereas beta‑blockers reduce heart rate and calcium‑channel blockers relax vascular smooth muscle through different mechanisms. Choice of therapy depends on patient profile, comorbidities, and tolerance, and clinicians often combine agents for optimal symptom control.

Store Monorem R at ambient temperature below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Monorem R is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed, or broken unless specifically instructed.

Serious adverse events include severe hypotension, syncope, and allergic reactions such as rash or angioedema. Patients experiencing sudden dizziness, fainting, or signs of an allergic response should seek immediate medical attention.

Monorem R should be avoided in patients with known hypersensitivity to isosorbide mononitrate or any nitrate, those who have taken phosphodiesterase‑5 inhibitors within 24 hours, and individuals with severe anemia or uncontrolled hypotension unless a physician determines it is safe.